Avalo Therapeutics (AVTX) Stock Forecast & Price Target

Avalo Therapeutics is supported by a compelling clinical thesis for abdakibart, whose Phase 2 LOTUS data showed statistically significant HiSCR75 benefit with a 42.5% combined response and a clean safety profile, while also improving draining tunnels and other disease-burden measures. The company’s differentiation is reinforced by selective, high-affinity IL-1β targeting, longer half-life, and more convenient dosing than broader IL-1 approaches, which could support a meaningful later-line role in hidradenitis suppurativa despite competition from IL-17 therapies. Financially, AVTX reported an $18.9M net loss in third quarter but ended with $462.8M in cash, expected to fund operations into 2029, giving it balance-sheet strength to reach planned Phase 3 initiation in 1H27.

Avalo Therapeutics is pressured by INTREPID’s 8-point placebo-adjusted HiSCR75 benefit, which was far below the 17.2-point LOTUS result and well under the 20-plus-point efficacy needed to support a differentiated HS profile. That contraction, combined with the fact that the 1,400-patient pivotal study still suggests IL-1 may lag IL-17 therapies, weakens confidence that abdakibart can sustain its Phase 2 promise in Phase 3 and limits the commercial case for monthly dosing. Financially, the company’s ~$425M market cap sits below its $472.2M cash and investments reported at June 30, so cash now anchors valuation while both abdakibart and AVTX-010 remain exposed to the same pathway risk.